Barasertib

DB11747InvestigationalSmall molecule

Barasertib has been used in trials studying the treatment of Tumors, Lymphoma, Solid Tumors, Solid Tumours, and Myeloid Leukemia, among others.

Chemical structure of Barasertib
Mechanism
Curator reviewed
Formula / weight
C26H31FN7O6P · 587.549 g/mol (avg)
Code names
AZD-1152

Resolves to

Compound
UNII16XC2U7W8NCAS722543-31-9ChEMBLCHEMBL415049PubChem11497983
Structure
InChIKeyGBJVVSCPOBPEIT-UHFFFAOYSA-NSMILESCCN(CCCOC1=CC=C2C(NC3=CC(CC(=O)NC4=CC=CC(F)=C4)=NN3)=NC=NC2=C1)CCOP(O)(O)=O
Targets
Q96GD4AURKB

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Barasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In